Omeros Co. (NASDAQ:OMER) Shares Bought by Ancora Advisors LLC

Ancora Advisors LLC increased its holdings in shares of Omeros Co. (NASDAQ:OMER - Free Report) by 1,036.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 85,800 shares of the biopharmaceutical company's stock after acquiring an additional 78,250 shares during the quarter. Ancora Advisors LLC owned about 0.15% of Omeros worth $848,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Truvestments Capital LLC grew its holdings in shares of Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 1,669 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after buying an additional 1,972 shares during the period. Cerity Partners LLC increased its holdings in shares of Omeros by 9.9% during the 4th quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company's stock worth $286,000 after buying an additional 2,600 shares during the last quarter. Mindset Wealth Management LLC raised its position in shares of Omeros by 4.8% during the 4th quarter. Mindset Wealth Management LLC now owns 63,000 shares of the biopharmaceutical company's stock valued at $622,000 after buying an additional 2,875 shares during the period. Finally, SG Americas Securities LLC lifted its holdings in Omeros by 21.2% in the fourth quarter. SG Americas Securities LLC now owns 24,361 shares of the biopharmaceutical company's stock valued at $241,000 after acquiring an additional 4,257 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company's stock.

Omeros Stock Performance

Shares of NASDAQ OMER traded down $0.13 during trading on Friday, reaching $6.18. The stock had a trading volume of 521,705 shares, compared to its average volume of 591,517. The business's 50-day moving average price is $7.43 and its 200-day moving average price is $8.15. Omeros Co. has a fifty-two week low of $3.00 and a fifty-two week high of $13.60. The company has a market cap of $360.33 million, a P/E ratio of -2.68 and a beta of 2.42.

Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $0.08. During the same quarter in the previous year, the business earned ($0.15) EPS. Analysts forecast that Omeros Co. will post -3.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. D. Boral Capital reissued a "buy" rating and set a $36.00 target price on shares of Omeros in a research note on Wednesday. StockNews.com lowered shares of Omeros from a "hold" rating to a "sell" rating in a report on Wednesday, April 9th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research report on Tuesday, April 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $22.50.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.